These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 22222314)

  • 1. Restoration of the blood pressure circadian rhythm by direct renin inhibition and blockade of angiotensin II receptors in mRen2.Lewis hypertensive rats.
    Moniwa N; Varagic J; Ahmad S; VonCannon JL; Ferrario CM
    Ther Adv Cardiovasc Dis; 2012 Feb; 6(1):15-29. PubMed ID: 22222314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hemodynamic and hormonal changes to dual renin-angiotensin system inhibition in experimental hypertension.
    Moniwa N; Varagic J; Ahmad S; VonCannon JL; Simington SW; Wang H; Groban L; Brosnihan KB; Nagata S; Kato J; Kitamura K; Gomez RA; Lopez ML; Ferrario CM
    Hypertension; 2013 Feb; 61(2):417-24. PubMed ID: 23232645
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aliskiren, a novel, orally effective renin inhibitor, lowers blood pressure in marmosets and spontaneously hypertensive rats.
    Wood JM; Schnell CR; Cumin F; Menard J; Webb RL
    J Hypertens; 2005 Feb; 23(2):417-26. PubMed ID: 15662231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term safety, tolerability and efficacy of aliskiren in combination with valsartan in patients with hypertension: a 6-month interim analysis.
    Chrysant SG; Murray AV; Hoppe UC; Dattani D; Patel S; Hsu H; Zhang J
    Curr Med Res Opin; 2008 Apr; 24(4):1039-47. PubMed ID: 18307835
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aliskiren improves left ventricular dysfunction and reduces cardiac dilation in Syrian cardiomyopathic hamsters.
    Crespo MJ; Cangiano JL; Altieri PI; Escobales N
    J Cardiovasc Pharmacol; 2012 Jun; 59(6):547-52. PubMed ID: 22370958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Valsartan chronotherapy reverts the non-dipper pattern and improves blood pressure control through mediation of circadian rhythms of the renin-angiotensin system in spontaneous hypertension rats.
    Yang K; Wang Y; Ding Y; Cui H; Zhou D; Chen L; Ma Z; Wang W; Zhang W; Luan J
    Chronobiol Int; 2019 Aug; 36(8):1058-1071. PubMed ID: 31096810
    [No Abstract]   [Full Text] [Related]  

  • 7. Aliskiren enhances the protective effects of valsartan against cardiovascular and renal injury in endothelial nitric oxide synthase-deficient mice.
    Yamamoto E; Kataoka K; Dong YF; Nakamura T; Fukuda M; Tokutomi Y; Matsuba S; Nako H; Nakagata N; Kaneko T; Ogawa H; Kim-Mitsuyama S
    Hypertension; 2009 Sep; 54(3):633-8. PubMed ID: 19597038
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of add-on aliskiren to type 1 angiotensin receptor blocker therapy on endothelial function and autonomic nervous system in hypertensive patients with ischemic heart disease.
    Ozeki A; Amiya E; Watanabe M; Hosoya Y; Takata M; Watanabe A; Kawarasaki S; Nakao T; Watanabe S; Omori K; Yamada N; Tahara Y; Hirata Y; Nagai R
    J Clin Hypertens (Greenwich); 2014 Aug; 16(8):591-8. PubMed ID: 25039889
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative efficacy of aliskiren/valsartan vs valsartan in nocturnal dipper and nondipper hypertensive patients: a pooled analysis.
    Giles TD; Alessi T; Purkayastha D; Zappe D
    J Clin Hypertens (Greenwich); 2012 May; 14(5):299-306. PubMed ID: 22533656
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination of direct renin inhibition with angiotensin type 1 receptor blockade improves aldosterone but does not improve kidney injury in the transgenic Ren2 rat.
    Whaley-Connell A; Habibi J; Nistala R; Hayden MR; Pulakat L; Sinak C; Locher B; Ferrario CM; Sowers JR
    Regul Pept; 2012 Jun; 176(1-3):36-44. PubMed ID: 22465166
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aliskiren and valsartan combination therapy for the management of hypertension.
    Epstein BJ
    Vasc Health Risk Manag; 2010 Sep; 6():711-22. PubMed ID: 20859542
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hormonal and hemodynamic effects of aliskiren and valsartan and their combination in sodium-replete normotensive individuals.
    Azizi M; Ménard J; Bissery A; Guyene TT; Bura-Rivière A
    Clin J Am Soc Nephrol; 2007 Sep; 2(5):947-55. PubMed ID: 17702736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beneficial cardiac effects of the renin inhibitor aliskiren in spontaneously hypertensive rats.
    van Esch JH; Moltzer E; van Veghel R; Garrelds IM; Leijten F; Bouhuizen AM; Danser AH
    J Hypertens; 2010 Oct; 28(10):2145-55. PubMed ID: 20625318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Despite similar reduction of blood pressure and renal ANG II and ET-1 levels aliskiren but not losartan normalizes albuminuria in hypertensive Ren-2 rats.
    Vaňourková Z; Kramer HJ; Husková Z; Cervenka L; Vaněčková I
    Physiol Res; 2010; 59(3):339-345. PubMed ID: 20666571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The antihypertensive effectiveness and safety of dual RAAS blockade with aliskiren and valsartan.
    Chrysant SG
    Drugs Today (Barc); 2010 Mar; 46(3):151-62. PubMed ID: 20467589
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in double-transgenic rats.
    Pilz B; Shagdarsuren E; Wellner M; Fiebeler A; Dechend R; Gratze P; Meiners S; Feldman DL; Webb RL; Garrelds IM; Jan Danser AH; Luft FC; Müller DN
    Hypertension; 2005 Sep; 46(3):569-76. PubMed ID: 16103264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predominance of AT(1) blockade over mas-mediated angiotensin-(1-7) mechanisms in the regulation of blood pressure and renin-angiotensin system in mRen2.Lewis rats.
    Varagic J; Ahmad S; VonCannon JL; Moniwa N; Brosnihan KB; Wysocki J; Batlle D; Ferrario CM
    Am J Hypertens; 2013 May; 26(5):583-90. PubMed ID: 23459599
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blood pressure and plasma renin activity responses to different strategies to inhibit the renin-angiotensin-aldosterone system during exercise.
    Williams B; Baschiera F; Lacy PS; Botha J; Prescott MF; Brunel P
    J Renin Angiotensin Aldosterone Syst; 2013 Mar; 14(1):56-66. PubMed ID: 22859712
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renin inhibitor aliskiren improves impaired nitric oxide bioavailability and protects against atherosclerotic changes.
    Imanishi T; Tsujioka H; Ikejima H; Kuroi A; Takarada S; Kitabata H; Tanimoto T; Muragaki Y; Mochizuki S; Goto M; Yoshida K; Akasaka T
    Hypertension; 2008 Sep; 52(3):563-72. PubMed ID: 18645051
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aliskiren reduces myocardial ischemia-reperfusion injury by a bradykinin B2 receptor- and angiotensin AT2 receptor-mediated mechanism.
    Koid SS; Ziogas J; Campbell DJ
    Hypertension; 2014 Apr; 63(4):768-73. PubMed ID: 24420538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.